$PLPL Plandaí’s near term objective is to undertake the profiling of the Phytofare™ Cannabinoid Complex with in-vitro testing starting within six months, followed by animal trials, with the expectation that it will obtain FDA consent to commence human clinical trials specifically aimed at targeted neural disorders.

As Plandaí achieves milestones events, greater awareness and attention will likely be afforded the company and its stock.